GELSNasdaqPharmaceutical PreparationsFiscal year ends June 30
Gelteq Ltd
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Nov 17, 2025
$0.43−0.02 (-3.50%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2022 to 2025
Operating margin
-3317.7%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2022 | FY2022 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | – | 0.24 | |
| Net debt to EBITDA | – | – | -1.89× | |
| Interest coverage | – | – | -2.8× | |
| Capex to revenue | – | – | 1.9% | |
| Diluted shares | – | – | 9M |
Cash use needs five years of cash flow figures
Gelteq does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 4 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-A$5.52M
- Return on assets improvedROA up on the prior year-15.8% → –
- Earnings backed by cashOperating cash flow above net income-A$5.52M vs –
- Less leverageLong-term debt to assets fell8.5% → 0.1%
- Better liquidityCurrent ratio rose0.08 → 0.24
- No dilutionShare count did not rise8M → 9M
- Gross margin improvedGross margin up on the prior year– → 30.33%
- More efficientAsset turnover rose– → 0.01